Member Info for EmeraldCarrots

11 was his age. In fact as there is no age bar on this site it could be true. I mean, who knows! Amers should put me on filter too as that poster brings nothing of use to this site.

Astrazeneca could do with dual analysis. Don't they want to sell22 Jul 2025 08:56

More targeted drugs whereby the patient is selected if their cancer displays certain cancer biomarkers!? They can about double the amount of biomarkers found using dual analysis....................

“dual analysis” official announcement 04/01/2024:-

https://www.londonstockexchange.com/news-article/AGL/breakthrough-clinical-results/16274813

Follow on announcement 17/06/2025:-

https://www.londonstockexchange.com/news-article/AGL/eacr-2025-data-demonstrating-dna-dual-analysis/17088953

EACR 2025: Data demonstrating DNA dual analysis 17/06/2025

https://www.londonstockexchange.com/news-article/AGL/eacr-2025-data-demonstrating-dna-dual-analysis/17088953

Potentially one test to enable the selection of the most appropriate cancer drug..........

A test using just a standard blood sample than can be done at the doctors.

All IMHO.

IMHO. Indeed when dual analysis is used by any Pharma Co during a cancer drug trial then the sp will go 30p, really. Angle's lab has confirmed the results of dual analysis find around twice an many biomarkers as CtDna analysis on it's own. Biomarkers are used by modern drugs to target cancerous cells. Independant labs have confirmed too. So what Pharma Plc will sign up first? You know it makes sense! I know you are s l o w to do A N Y T H I N G you big pharma co's. Yawn.......... Are the top people at Astrazeneca just slow or a bit thick? LOL!

All IMHO.

Tick up.

Where will the sp be then? 4p? 5p? 6p?

A 774,728 showing now.

Roger65.

I find you posts amusing. I have zero confidence in anything you post I might add. LOL!

Far compared to 6 months ago. In fact they may avoid a placing, depends on the International orders they are keeping quiet about. Remember the initial ones reported in the RNS of 20/12/2023. As in France, Austria, Greece, Saudi Arabia, Turkey and the Netherlands. The market ASSUMES nothing at all came from those. Oh, and Italy of course. It seems unlikely that all these 7 would have binned the machine since then. LOL!!!

All IMHO.

My average is below theirs of course.

Have not exactly workd out for them. Almost a 50% loss in 7 months!

Won't be able to buy at the placing price as I'm sure you know. Of course if they can invoice part of the £800K Scottish rollout soon maybe they won't have to do one? Especially with at least 16 hospitals using the Genedrive® MT-RNR1 in the UK. If all those have 2 machines as is likely then thats 32......... or more.

The negative posts on here? I have at least bothered to find out what hositals currently use the Genedrive® MT-RNR1. That is ones that have been confirmed as users in various RNS's. I have a spreadsheet with what hospitals, names and all. "A clinical expert said that centres may need more than 1 Genedrive system to successfully implement the test, and the company noted that Saint Mary's Hospital in Manchester has 2 systems in use.". So I know there are 16 hospitals using at least one machine, and it's quite likely that is in fact 2 machines. 16 or 32 machines in use then?

Amers. Can you point me to any of your posts that have some actual facts taken fro official RNS's that might be of interest to anybody?

All IMHO.

Is coming. Other holders panic and sell out. Just before the news arrives (you know when) buy back in at the lower level and reap the rewards. This does happen. You just need to know when good news is going to arrive (for sure). We will see. GDR are doing a lot, lot better than some people think IMHO. 30 to 40 hospitals might be users by year end. That assumes no new international sales at all! We will see!!!

From that, and with by then 14 hospitals in the long term Genedrive® MT-RNR1 test program etc. By year end there should be around 30 hospitals using the Genedrive® MT-RNR1 in the UK. At least 6 hospitals abroad we already know about. 30 to 40 hospitals using the Genedrive® MT-RNR1 7 days a week, 52 weeks a year.

LOL!

- The Genedrive® MT-RNR1 should be in use at 16 + the 5 = 21 Hospitals in the next few months. So 21 neonatal wards using the machine 24/7. Assuming 1 machine per hospital and that may be in fact 2.

Against the offered pay deal. However, unless GDR update us, we don't know about new installations, especially international ones. Looking at the orders compared to a year ago I bet GDR are very busy preparing for and doing new installations. The expansion of the use of the Genedrive's CYP2C19-ID to include Acute Coronary Syndrome, the rollout of the Genedrive® MT-RNR1 up to the 14 hospitals (currently 9) and the Scottish rollout of the Genedrive® MT-RNR1 another 10?. They are busy and each installation has the initial payment of around £5,000 per machine followed by the consumables they need going forward. I suspect we will get an update as with no news the sp is unlikely to move.

All IMHO.

Apart from possibly saving a baby from being rendered deaf any Hospital insurance Company should be very happy the machine is used. These should be selling like hot cakes so there is a marketing problem that needs addressing. Genedrive should try to get articles in European medical magazines to get the word out. It's a fantastic product that can save loads of money and stop years of misery for babies and their parents.

I think so. Massively.

Any of the International orders were initially to one hospital one assumes. Could lead to many more, especially if they are private hospitals that are part of a chain. Insurance Co's should like their use as less claims for babies being rendered deaf.